Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal Cancer

百時美施貴寶(Bristol-Myers)的放化療聯合方案與食管癌的總體生存效益

Benzinga Real-time News · 2021/04/08 20:02

Bristol-Myers Squibb Co (NYSE: BMY) has announced positive topline results from Phase 3 CheckMate 648 trial evaluating Opdivo (nivolumab) plus chemotherapy or Opdivo plus BMY's Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Opdivo plus chemotherapy demonstrated a statistically significant and clinically meaningful benefit for the primary and secondary endpoints of overall survival (OS) in patients whose tumors express PD-L1.
Additionally, Opdivo/chemotherapy combo demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) by blinded independent central review.
Opdivo plus Yervoy also met its primary and secondary endpoints by demonstrating statistically significant and clinically meaningful overall survival improvements. Still, the combo did not meet its other primary endpoint of progression-free survival.
The company will complete an evaluation of the CheckMate -648 data and looks forward to sharing the results at an upcoming medical conference, as well as with health authorities.
Price Action: BMY shares are up 0.3% at $62.26 in premarket trading on the last check Thursday.

百時美施貴寶公司紐約證券交易所股票代碼：BMY)宣佈了CHECKMATE 648期試驗的陽性結果，該試驗評估了Opdivo(Nivolumab)加化療或Opdivo加BMY‘s Yerway(Ipilimumab)治療不能切除的晚期或轉移性食管鱗癌(ESCC)。
在腫瘤表達PD-L1的患者中，Opdivo加化療對總生存期(OS)的主要和次要終點有統計學意義和臨牀意義。
此外，Opdivo/化療組合通過盲目的獨立中心審查，在無進展生存(PFS)的主要終點方面顯示出統計上顯著和臨牀上有意義的改善。
Opdivo Plus伊爾沃伊還通過展示統計上顯著的和臨牀上有意義的總體存活率改善，滿足了它的主要和次要終點。儘管如此，這一組合並沒有達到無進展生存的另一個主要終點。
該公司將完成對Check Mate-648數據的評估，並期待着在即將到來的醫學會議上以及與衞生當局分享結果。
價格行動：在週四的盤前交易中，BMY股價上漲0.3%，至62.26美元。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

風險及免責聲明